1711P Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Year: 2024
Type: article
Abstract: In the current landscape IMDC prognostic group has been used as a surrogate for treatment choices in 1st line metastatic renal cell carcinoma (mRCC) in clinical trials. This has resulted in distinction between IMDC intermediate & poor risk (IR/PR) group compared to IMDC favourable risk (FR) group wherein, IR/PR IMDC groups get analysed as one treatment group. With clinical equipoise with IOTKI and IOIO in IR/PR group, we have dissected outcomes of 1st line systemic anticancer therapy (SACT) in mRCC by IMDC groups.
Source: Annals of Oncology
Authors: J. McGrane, R. Frazer, A. Bahl, A. Challapalli, P. Roy, M. Tuthill, C. Forde, J.M. Malik, X-Y. Jiang, S.M. Alam, E.C.E. Jones, N. Charnley, W.M. Mohamed, N.O. Moon, D. Parslow, T.R. Geldart, C.L. Dyke, J.C. Tapia, D. Lee, G.J. Melendez-Torres
Institutions: Royal Cornwall Hospital Trust, Royal Cornwall Hospital, National Health Service Wales, Velindre Cancer Centre, Velindre NHS Trust, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Belfast Health and Social Care Trust, The Northern Ireland Cancer Centre, NHS Lothian, Freeman Hospital, Mount Vernon Cancer Centre, Southampton General Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Singleton Hospital, Plymouth Hospital, University Hospitals Plymouth NHS Trust, Poole Hospital, Poole Hospital NHS Foundation Trust, Torbay Hospital, University of Exeter
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,600
OpenAlex ID: W4402704852